Skip to content
★ Sign in to follow
GU

Genertec Universal Medical Group Co. Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$9.3BBanks

No insider purchase over the last 90 days. The latest, by LIU Zhiyong, was filed 22 Apr 2020.

Genertec Universal Medical Group Co. Ltd.: what insiders have been doing

Genertec Universal Medical Group Co. Ltd. is a Banks company based in People's Republic of China. Its directors and officers file their transactions with HKEX. Genertec Universal Medical Group Co. Ltd. has had no insider filing for more than a year; the last one goes back to 29 July 2025.

The full history, which starts in 2018, counts 17 purchases against no sales.

For comparison within the same sector, see the insider buying recorded at ASR Nederland N.V. and Avarda Bank AB. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Key facts

Headquarters: People's Republic of China

Source: Wikidata (CC0).

Insider Decl.
19
Thresholds
n/a
Buy Volume
€3M
17 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 22 Apr 2020 · 2391 days ago · €64k
    +37.7%
    Entry HK$4.70 · Close at T+365 HK$6.47
  • Filed 10 Jul 2018 · 3043 days ago · €130k
    -1.4%
    Entry HK$6.23 · Close at T+365 HK$6.14

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 7,698 of 26,911 companies
62.3
score / 100
Value
75
Quality
49
FCF yld52%
Earn yld23%
EV/EBITDA16.0x
ROE9.6%
Gross mgn34%
Net mgn14%
Debt/EBITDA13.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$4.60
Analyst consensus
1 analysts
·
HK$6.76Target HK$6.76(+47%)HK$6.76
Income statement
RevenueHK$14.9B
Gross profitHK$5B34% margin
EBITDAHK$3.9B26% margin
Net incomeHK$2.2B15.9% margin
Valuation
PER (trailing)3.8x
PER (forward)4.1x
P/Book0.4x
Beta0.57
Balance sheet & cash
Market capHK$9.3B
Total debtHK$52.7B
Free Cash FlowHK$4.8B
Debt / Equity192%
Profitability & ownership
ROE9.6%
ROA2.7%
% insiders38.0%
% institutions29.3%
Last declaration on 29 July 2025
Declarations19 total
  • ●
    DirectorExecutives
    0HKEX
    30,000 sharesShareXHKGHKEX:DA20250729E00054
  • ●
    DirectorExecutives
    0HKEX
    30,000 sharesShareXHKGHKEX:DA20220623E00044
  • ▲
    DirectorExecutives
    534,735 HKD17HKEX
    116,500 shares@ HK$4.5958.0% of flowShareXHKGHKEX:DA20200422E00039
    Canonical exit: 20 Jul 2020 (T+90)
  • ▲
    DirectorExecutives
    230,000 HKD13HKEX
    50,000 shares@ HK$4.6025.0% of flowShareXHKGHKEX:DA20200421E00162
    Canonical exit: 15 Jul 2020 (T+90)
  • ▲
    DirectorExecutives
    156,780 HKD13HKEX
    33,500 shares@ HK$4.6817.0% of flowShareXHKGHKEX:DA20200421E00163
    Canonical exit: 16 Jul 2020 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    1,322,000 sharesShareXHKGHKEX:DA20200106E00075
    Canonical exit: 30 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    1,322,000 sharesShareXHKGHKEX:DA20200106E00078
    Canonical exit: 30 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    1M HKD11HKEX
    200,000 shares@ HK$5.9664.8% of flowShareXHKGHKEX:DA20180710E00138
    Canonical exit: 3 Oct 2018 (T+90)
  • ▲
    DirectorExecutives
    904,995 HKD11HKEX
    150,000 shares@ HK$6.03333.6% of flowShareXHKGHKEX:DA20180709E00111
    Canonical exit: 2 Oct 2018 (T+90)
  • ▲
    DirectorExecutives
    603,500 HKD11HKEX
    100,000 shares@ HK$6.0352.4% of flowShareXHKGHKEX:DA20180706E00182
    Canonical exit: 1 Oct 2018 (T+90)
  • ▲
    DirectorExecutives
    232,925 HKD11HKEX
    38,500 shares@ HK$6.050.9% of flowShareXHKGHKEX:DA20180705E00124
    Canonical exit: 27 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD12HKEX
    219,000 shares@ HK$5.99835.3% of flowShareXHKGHKEX:DA20180704E00132
    Canonical exit: 26 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    2M HKD12HKEX
    300,000 shares@ HK$6.11937.4% of flowShareXHKGHKEX:DA20180703E00171
    Canonical exit: 25 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    4M HKD12HKEX
    600,000 shares@ HK$6.183314.9% of flowShareXHKGHKEX:DA20180629E00162
    Canonical exit: 24 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    3M HKD12HKEX
    400,000 shares@ HK$6.37510.3% of flowShareXHKGHKEX:DA20180626E00202
    Canonical exit: 19 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    1M HKD12HKEX
    206,000 shares@ HK$6.34715.3% of flowShareXHKGHKEX:DA20180625E00124
    Canonical exit: 18 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    3M HKD12HKEX
    480,000 shares@ HK$6.375612.3% of flowShareXHKGHKEX:DA20180622E00115
    Canonical exit: 17 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    2M HKD12HKEX
    250,000 shares@ HK$6.56946.6% of flowShareXHKGHKEX:DA20180621E00213
    Canonical exit: 13 Sept 2018 (T+90)
  • ▲
    DirectorExecutives
    7M HKD14HKEX
    1,000,000 shares@ HK$6.9226.2% of flowShareXHKGHKEX:DA20180404E00195
    Canonical exit: 26 Jun 2018 (T+90)

19 of 19 declarations

About Genertec Universal Medical Group Co. Ltd.

Genertec Universal Medical Group Co. Ltd. is a company specializing in the provision of medical services and products. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations